The burst release of insulin from depot‐based systems may result in hypoglycemia, which may cause a variety of symptoms including behavioral and cognitive disturbance, seizure, loss of consciousness, brain damage, and even death.136 A combination delivery system137 that can simultaneously release glucagon in response to low BGLs is envisioned to avoid risk of hypoglycemia. Here, INS is linked to Hypoglycemia.